top of page

Introducing the Health Technology Evaluation Pathway (HTEP)

  • ispornewzealand
  • 17 hours ago
  • 2 min read

Tuesday 21 April, 10am


We are delighted to welcome James Le Fevre, Anita Fitzgerald, Gina Morgan, and Grant Lee from Health New Zealand | Te Whatu Ora to present our next ISPOR NZ webinar, introducing the Health Technology Evaluation Pathway (HTEP) and its role in supporting decisions on the adoption of new health technologies in Aotearoa New Zealand.


The webinar will be held via Zoom at 10am on Tuesday 21 April. To register, please complete the form on this page.


Abstract

Health New Zealand has developed the Health Technology Evaluation Pathway (HTEP) to support a nationally consistent and transparent approach to assessing health technologies. HTEP considers both new and existing health technologies where there is a need to inform investment, disinvestment, or changes in use.

 

This webinar will introduce the rationale for establishing HTEP and outline its overall design, including how technologies enter the pathway, key decision points, and triaging rules. The presenters will describe the role of economic evaluation in the HTEP and discuss how evidence is used to inform decisions on the adoption of new technologies within the publicly funded health system. Selected case examples will be used to illustrate how technologies move through HTEP in practice.


About the speakers

James Le Fevre, Anita Fitzgerald, Gina Morgan, and Grant Lee are senior staff at Health New Zealand | Te Whatu Ora who were closely involved in the design and establishment of the Health Technology Evaluation Pathway (HTEP). Their collective experience spans health technology assessment, evidence appraisal, clinical medicine and health service planning. Together, they bring a practical perspective on how structured evaluation processes can support consistent, evidence‑informed decisions about the adoption of new health technologies within the New Zealand health system.

Comments


© 2024 by International Society for Pharmacoeconomics and Outcomes Research (ISPOR) NZ Chapter

bottom of page